Maze Therapeutics’ Chief Medical Officer Sold 100% of His Direct Holdings. Here’s What This Means for Investors.
Maze Therapeutics is a clinical-stage biotechnology company leveraging genetic insights to develop precision medicines for complex diseases. With a focused pipeline in renal and metabolic disorders, Maze Therapeutics aims to advance novel small molecule therapies through clinical development. The company targets patients with chronic kidney and metabolic diseases, with a focus on addressing unmet medical needs in the United States healthcare market. How does the transaction size relate to Bernstein’s recent trading activity? While Bernstein’s earlier administrative transactions involved a range of trade sizes, this complete disposition of direct shares reflects the culmination of a multi-step reduction strategy, consistent with declining direct holdings capacity over recent months. What portion of Bernstein’s total holdings did this trade represent, and are there other classes involved? This transaction represented 100% of Bernstein’s direct Common Stock holdings. Was this sale routine or discretionary, and what is the derivative context? The sale involved the exercise of 15,000 options, immediately converted to shares and sold. How does this transaction affect Harold Bernstein’s exposure to Maze Therapeutics? Bernstein’s direct Common Stock holdings were reduced to zero; however, his beneficial exposure continues via 237,407 directly held outstanding stock options, providing the ability to acquire Common Stock in the future. Maze Therapeutics (NASDAQ:MAZE) R&D President and Chief Medical Officer Harold Bernstein reported a sale of 15,000 shares of Common Stock for a total of approximately $442,000 on April 1, 2026, through an exercise of options with immediate disposition, as disclosed in a SEC Form 4 filing . Story Continues What this transaction means for investors The complete disposition of all directly-held Maze Therapeutics shares on April 1 by Chief Medical Officer Harold Bernstein is not necessarily a red flag. He sold the stock as part of his Rule 10b5-1 trading plan, adopted in September of 2025. A Rule 10b5-1 trading plan is frequently implemented by insiders to avoid accusations of making trades based on insider information. Moreover, he retains over 237,000 stock options. Bernstein’s sale came at a time when Maze Therapeutics stock was experiencing a decline. Shares hit a 52-week high of $53.65 in March, thanks to encouraging clinical trial data. But with a soaring valuation, investors began cashing in, which led to the drop. Currently, Maze Therapeutics does not produce revenue. It exited 2025 with a net loss of $131.1 million. Despite the recent fall in share price, investing in the company entails high risk. Investors should have conviction that its lead kidney drug, MZE829, can eventually achieve federal approval before deciding to buy shares. Should you buy stock in Maze Therapeutics right now? Before you buy stock in Maze Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Maze Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $532,066!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,087,496!* Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 185% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of April 4, 2026. Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Maze Therapeutics’ Chief Medical Officer Sold 100% of His Direct Holdings. Here’s What This Means for Investors. was originally published by The Motley Fool